BioVie Inc
BIVI
查看詳細走勢圖
1.410USD
-0.040-2.76%
收盤 12/19, 16:00（美東）報價延遲15分鐘
10.63M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-2.76%
5天
-2.76%
1月
+2.92%
6月
-87.06%
今年開始到現在
-92.95%
1年
-93.22%
查看詳細走勢圖
TradingKey BioVie Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
BioVie Inc當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名200/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價12.00。中期看，股價處於下降通道。近一個月，市場表現較強，基本面評分較高，但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
BioVie Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
1
分析師
買入
評級
12.000
目標均價
+654.72%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
BioVie Inc亮點
亮點風險
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
估值高估
公司最新PE估值-0.23，處於3年歷史高位
先鋒集團持倉
明星投資者先鋒集團持倉，最新持倉128.93K股
BioVie Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
BioVie Inc簡介
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
公司代碼BIVI
公司BioVie Inc
CEODo (Viet Cuong Viet)
網址https://www.bioviepharma.com/
常見問題
BioVie Inc(BIVI)的當前股價是多少？
BioVie Inc(BIVI)的當前股價是 1.410。
BioVie Inc 的股票代碼是什麼？
BioVie Inc的股票代碼是BIVI。
BioVie Inc股票的52週最高點是多少？
BioVie Inc股票的52週最高點是25.764。
BioVie Inc股票的52週最低點是多少？
BioVie Inc股票的52週最低點是1.250。
BioVie Inc的市值是多少？
BioVie Inc的市值是10.63M。
BioVie Inc的淨利潤是多少？
BioVie Inc的淨利潤為-17.91M。
現在BioVie Inc(BIVI)的股票是買入、持有還是賣出？
根據分析師評級，BioVie Inc(BIVI)的總體評級為買入，目標價格為12.000。
BioVie Inc(BIVI)股票的每股收益（EPS TTM）是多少
BioVie Inc(BIVI)股票的每股收益（EPS TTM）是-6.111。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
